Modern diagnostics in chronic myeloproliferative diseases (CMPDs)

Area of Science:

• Hematology
• Oncology
• Clinical Pathology

Background:

• The World Health Organization (WHO) classifies chronic myeloproliferative diseases (CMPDs) into distinct entities, including chronic myeloid leukemia (CML), polycythemia vera (PV), and essential thrombocythemia (ET).
• CMPDs exhibit diverse clinical features and laboratory findings, necessitating specific diagnostic strategies for accurate classification.
• Effective management and monitoring of treatment response, particularly for minimal residual disease (MRD), require robust diagnostic methodologies.

Purpose of the Study:

• To outline essential laboratory diagnostic approaches for CMPDs at initial diagnosis.
• To detail laboratory follow-up strategies for monitoring treatment efficacy and MRD in CMPDs.
• To emphasize the therapeutic implications of comprehensive diagnostic panels in CMPD management.

Main Methods:

• Utilizing a comprehensive diagnostic panel including cytomorphology.
• Employing cytogenetic analysis for chromosomal abnormalities.
• Implementing molecular genetic methods for specific mutations and disease markers.

Main Results:

• A multi-faceted diagnostic approach is essential for precise classification of various CMPDs.
• Integrated laboratory testing enables effective monitoring of treatment response and minimal residual disease (MRD).
• The diagnostic strategy directly influences treatment optimization and patient management.

Conclusions:

• Establishing the correct diagnosis in CMPDs relies on a combination of cytomorphology, cytogenetics, and molecular genetics.
• Comprehensive diagnostic evaluation is critical for optimizing therapeutic strategies and assessing treatment outcomes.
• Accurate diagnosis and follow-up are paramount for managing patients with chronic myeloproliferative diseases.